What Is Daraxonrasib, and How Does It Work?

Daraxonrasib is an investigational oral medication developed by Revolution Medicines, a clinical-stage oncology company based in Redwood City, California. It belongs to a new class of drugs called RAS (ON) inhibitors.

RAS mutations are the central molecular driver of pancreatic cancer, present in about 90% of cases. When functioning normally, RAS proteins act like molecular switches, toggling cell growth on and off. In cancer, these proteins become stuck in the "on" position, continuously signaling cells to grow.

For decades, oncologists considered RAS "undruggable" because the protein’s surface offered no convenient pocket for a drug molecule to bind. Early efforts to inhibit RAS signaling only produced marginal benefits for patients.

Daraxonrasib works differently. It is a multi-selective, non-covalent inhibitor that targets both mutant and wild-type RAS proteins in their active state, blocking the downstream signals that drive tumor growth. This broader targeting strategy is what makes it distinctive, and what makes it challenging to tolerate.

Where Is It in the FDA Approval Process?

Daraxonrasib has not yet been approved for use, but it has accumulated significant momentum. The U.S. Food and Drug Administration has granted the drug several special statuses, including Breakthrough Therapy Designation and Orphan Drug Designation for previously treated metastatic pancreatic cancer with specific mutations, specifically G12 mutations.

It was also selected for the FDA Commissioner’s National Priority Voucher program, an initiative launched in June 2025 to accelerate development of therapies aligned with national health priorities. This entitles Revolution Medicines to a faster FDA review when it submits a new drug application, potentially compressing the review timeline from standard periods to a matter of months.

Revolution Medicines said it intends to submit the new drug application to the FDA using this pathway in the near term, following the Phase 3 results announced this week.

A separate Phase 3 trial (RASolute 303) began enrolling patients in April 2026, testing daraxonrasib as a first-line treatment for newly diagnosed metastatic pancreatic cancer. Additional Phase 3 trials are underway in non-small cell lung cancer and other RAS-mutated tumor types.

If Revolution Medicines files its new drug application soon and the FDA grants priority review, approval could plausibly come by late 2026 or early 2027, though no official timeline has been announced. The drug would initially be approved for second-line use, meaning patients whose cancer has already progressed on a first treatment. Broader indications, including first-line use, would depend on data from the ongoing RASolute 303 trial.

Side Effects of Daraxonrasib

Sasse’s account of the drug’s side effects has drawn wide attention. "I take it orally, but it’s a nasty drug," he told the New York Post. "It causes crazy stuff like my body can’t grow skin and so I bleed all out of a whole bunch of parts of me that shouldn't be bleeding." His face, prominently featured in his podcast appearance, bore the marks of a severe skin reaction: bloody, peeling and raw.

In fact, skin toxicity is the signature side effect of daraxonrasib. The drug targets RAS signaling broadly, including in normal skin cells, which rely on RAS pathways for routine regeneration. It interferes with the skin's ability to repair itself.

The majority of patients in earlier trials experienced some degree of rash, though fewer than 10% developed a severe reaction. Cases like Sasse’s which involve skin bleeding have been described anecdotally by clinical investigators and are considered uncommon.

Managing the rash involves temporary dose interruptions, antibiotics and supportive care. No patients in the pivotal Phase 3 trial discontinued treatment due to rash alone. The drug’s overall safety profile was considered manageable with no new safety signals. Other side effects include nausea, fatigue and pain.

Understanding Pancreatic Cancer: The Deadliest of the Major Cancers

Pancreatic cancer accounts for roughly 3% of all cancer diagnoses in the United States but ranks as the third leading cause of cancer death. The five-year survival rate is approximately 13%.

The disease is almost never caught early. It produces few specific symptoms in its initial stages. Symptoms it does cause — like vague abdominal discomfort, back pain, unexplained weight loss and fatigue — can easily be attributed to other conditions. Jaundice, or yellowing of the skin, can occur in some patients but typically signals that the tumor has grown large enough to obstruct the bile duct.

There is no population-level screening for pancreatic cancer, so approximately 80-90% of patients are diagnosed with non-resectable disease (50-55% metastatic, 30-35% locally advanced) when surgery — the only potentially curative treatment — is no longer an option.

Pancreatic cancer has resisted treatment for reasons because of its biology. The tumor is surrounded by dense fibrous tissue that acts as a physical barrier, limiting the penetration of chemotherapy and immune cells. The local environment also suppresses immune activity. This is why immunotherapy, which has transformed outcomes in lung cancer and other cancer, has largely failed in pancreatic cancer.

What Comes Next in Pancreatic Cancer

Researchers are already thinking beyond daraxonrasib as a standalone agent. The Phase 3 results of daraxonrasib may be a foundation on which combination strategies can be built. For example, pairing RAS inhibition with chemotherapy or other targeted drugs to push survival further.

A drug that nearly doubles survival in the second-line setting could become the backbone of a first-line regimen if the ongoing trial data support it.

For patients and families facing a diagnosis that has long carried a near-certain prognosis, the arrival of daraxonrasib represents an inflection point. The drug is not a cure.

Sasse himself has been candid about that: the cancer has spread too widely, the disease too entrenched to be fully reversed. But the fact that a molecular target once considered untreatable is now yielding double-digit survival gains means the conversation about pancreatic cancer has changed fundamentally.